SARS-CoV-2 Membrane-, Envelope-, Nucleoprotein protein-VLP
宿主: SARS Coronavirus-2 (SARS-CoV-2)
宿主: HEK-293 Cells
VLP
ELISA, NTA, WB, LF
-
- 抗原
- SARS-CoV-2 Membrane-, Envelope-, Nucleoprotein
- 蛋白类型
- VLP
- 宿主
- SARS Coronavirus-2 (SARS-CoV-2)
-
资源
- HEK-293 Cells
- 应用范围
- ELISA, Nanoparticle Tracking Analysis (NTA), Western Blotting (WB), Lateral Flow (LF)
- 原理
- VLP of SARS-CoV-2 (M+E+N)
- 产品特性
- SARS-CoV-2 virus-like particles (VLP) were produced in HEK cells by co-expression of the membrane-, envelope- and nucleoprotein. The VLPs do not contain the viral genome, cannot replicate and are not infectious.
- 纯化方法
- Tangential flow filtration and polyethylene glycol precipitation
- Biological Activity Comment
- active
-
-
- 应用备注
-
Applications: Immunogenic antigen, antigen for ELISA and Western blot, reference for rapid antigen tests.
Western blot: 1-10 μg, ELISA: 1-5 μg/mL - 说明
-
Virus-like Particles are multiprotein complexes that resemble a native virus, but lack the genetic information. Therefore, VLPs are safe to handle in numerous fields of applications. For example, VLPs can be applied as antigen in serological assays (e.g. ELISA), or serve as reference material to standardize the performance of different diagnostic tests (e.g. rapid antigen tests or ELISA). Due to the self-adjuvanting properties of VLPs is the most common application of VLPs the use as antigen for immunizations for vaccine development or antibody discovery campaigns.
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- Lot specific
- 缓冲液
- PBS
- 储存条件
- -80 °C
- 储存方法
- - 80°C
-
- 抗原
- SARS-CoV-2 Membrane-, Envelope-, Nucleoprotein
- 背景
- SARS-CoV-2 (Severe acute respiratory syndrome coronavirus type 2) is a coronavirus (genus: Betacoronavirus, subgenus: Sarbecovirus) that was identified as the cause of COVID-19 disease in early 2020.
-
You are here:
